Literature DB >> 24852432

Revisiting the role of MCL1 in tumorigenesis of solid cancer: gene expression correlates with antiproliferative phenotype in breast cancer cells and its functional regulatory variants are associated with reduced cancer susceptibility.

Sheng Wang1, Yan Jiang, Jin Liu, Yuanyuan Zhao, Chan Xiang, Rong Ma, Haidong Gao, Li Jin, Fuchu He, Haijian Wang.   

Abstract

Compared to the well-defined anti-apoptotic role of myeloid cell leukemia sequence 1 (MCL1), its antiproliferative function in tumorigenesis is less studied. We had recently reported that regulatory variants of MCL1 contribute to enhanced promoter activity but reduced risk of lung cancer. We hypothesized that MCL1 expression may manifest antiproliferative phenotype and its functional variations may have etiological relevance for breast cancer. We manipulated MCL1 expression in MCF-7 cells and MDA231 with overexpression and knockdown, analyzed the effects on cell viability and cell cycling phase, and characterized the correlation with expression profiles of key regulators of cell cycle. We further genotyped the -190 insertion polymorphism and the neighboring single nucleotide polymorphisms (SNPs) in 745 breast cancer patients and 537 controls and analyzed their association with cancer risk. We confirmed that heightened expression of MCL1 resulted in decreased proliferation ability of breast cancer cells. We further observed that MCL1 overexpression in breast cancer cells resulted in cell cycle progression arresting in S phase and concomitant enhanced expression of p27, which could be rescued by p27 knockdown with co-transfection of small interfering RNA (siRNA). Furthermore, we found a significant reduction in breast cancer risk [odds ratio (OR) = 0.74; 95 % confidence interval (CI) = 0.59-0.93] associated with -190 insertion genotype; the expression-enhancing regulatory haplotype (OR 0.79; 95 % CI 0.66-0.95) and diplotype (OR 0.71; 95 % CI 0.57-0.89) were consistently associated with decreased cancer susceptibility. The study demonstrates that the expression-enhancing regulatory variants of MCL1 are protective modifiers of breast cancer risk, and reduced cell proliferation and arrested cell cycle progression partly mediated by p27 might be the underlying mechanism.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24852432     DOI: 10.1007/s13277-014-2108-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  40 in total

1.  Functional variable number of tandem repeats variation in the promoter of proto-oncogene PTTG1IP is associated with risk of estrogen receptor-positive breast cancer.

Authors:  Chan Xiang; Haidong Gao; Lei Meng; Zhaoyu Qin; Rong Ma; Yang Liu; Yan Jiang; Chengxue Dang; Li Jin; Fuchu He; Haijian Wang
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

2.  LDA--a java-based linkage disequilibrium analyzer.

Authors:  Keyue Ding; Kaixin Zhou; Fuchu He; Yan Shen
Journal:  Bioinformatics       Date:  2003-11-01       Impact factor: 6.937

3.  Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia.

Authors:  G Tobin; A Skogsberg; U Thunberg; A Laurell; A Aleskog; M Merup; C Sundström; G Roos; K Nilsson; R Rosenquist
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

4.  Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.

Authors:  Roberto L Vargas; Raymond E Felgar; Paul G Rothberg
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

5.  Re: Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia.

Authors:  Scott N Freeman; Gerold Bepler; Eric Haura; Rebecca Sutphen; W Douglas Cress
Journal:  J Natl Cancer Inst       Date:  2005-07-20       Impact factor: 13.506

6.  E2F-1 functions in mice to promote apoptosis and suppress proliferation.

Authors:  S J Field; F Y Tsai; F Kuo; A M Zubiaga; W G Kaelin; D M Livingston; S H Orkin; M E Greenberg
Journal:  Cell       Date:  1996-05-17       Impact factor: 41.582

7.  BCL-x(L) and BCL2 delay Myc-induced cell cycle entry through elevation of p27 and inhibition of G1 cyclin-dependent kinases.

Authors:  Courtney Greider; Anuja Chattopadhyay; Christina Parkhurst; Elizabeth Yang
Journal:  Oncogene       Date:  2002-11-07       Impact factor: 9.867

8.  Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation.

Authors:  G Vairo; T J Soos; T M Upton; J Zalvide; J A DeCaprio; M E Ewen; A Koff; J M Adams
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

Review 9.  The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.

Authors:  Isabel M Chu; Ludger Hengst; Joyce M Slingerland
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

10.  Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo.

Authors:  S Krajewski; S Bodrug; M Krajewska; A Shabaik; R Gascoyne; K Berean; J C Reed
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

View more
  2 in total

1.  Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.

Authors:  Jiang-Yong Yu; Si-Fan Yu; Shu-Hang Wang; Hua Bai; Jun Zhao; Tong-Tong An; Jian-Chun Duan; Jie Wang
Journal:  Chin J Cancer       Date:  2016-03-21

2.  MCL1 binding to the reverse BH3 motif of P18INK4C couples cell survival to cell proliferation.

Authors:  Robert H Whitaker; William J Placzek
Journal:  Cell Death Dis       Date:  2020-02-28       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.